Paris, France, April 4, 2024, 7:00 pm CET - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2024.
Information | Date* |
2024 1Q Cash Position | April 4, 2024 |
Annual General Meeting | May 29, 2024 |
2024 2Q Cash Position | July 23, 2024 |
2024 First-Half Financial Update and Statements | September 23, 2024 |
2024 3Q Cash Position | October 24, 2024 |
2024 4Q Cash Position | January 23, 2025 |
* This financial calendar is provided for information only and may be subject to changes. The Company's updated financial calendar is available on its corporate website.
Attachments
- Original Link
- Permalink
Disclaimer
Gensight Biologics SA published this content on 04 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 April 2024 17:14:04 UTC.